Recent Phase Ib trial results showed strong weight reduction and a favorable tolerability profile for Zealand Pharmas investigational amylin analog petrelintide, highlighting that GLP-1 receptor agonists are not the be-all and end-all of weight-loss treatments
What this means for you Even though CVS Caremark removed Zepbound from standard formularies, your employer might still choose to cover it
12 Dihydroxyacetone (DHA)
Functional medicine focuses on calming immune overactivation, repairing gut integrity, reducing inflammatory burden, and identifying triggers that keep the immune system stuck in attack mode
Symptoms include nausea, vomiting, bloating, feeling full quickly, and abdominal pain
Identified by CAS Number 2381089-83-2, Retatrutide is widely referenced in metabolic and obesity research literature as the first characterized triple agonist targeting the GIP receptor, GLP-1 receptor, and glucagon receptor (GCGR) simultaneously within a single molecular scaffold